Physician profile
Harry E Logue
NPI 1861476640
$1,662.29
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $992 · 2020: $524 · 2021: $147.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $489.29 | 2019-2021 | |
| Allergan, INC. | $236.94 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $148.78 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $141.41 | 2019-2020 | |
| Bausch Health US, LLC | $132.91 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $102.13 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $100.30 | 2019-2020 | |
| Shire North American Group INC | $53.04 | 2019 | |
| Avanir Pharmaceuticals, INC. | $49.05 | 2019-2021 | |
| Alkermes, INC. | $45.25 | 2019 | |
| Janssen Pharmaceuticals, INC | $44.63 | 2019 | |
| Neuronetics, INC. | $39.43 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.41 | 2019 | |
| Abbvie INC. | $24.24 | 2021 | |
| Adlon Therapeutics L.P. | $17.05 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $13.43 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Logue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.